Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770429 · ClinicalTrials.gov registry record · Phase 1
AZD6738 for Patients With Progressive MDS or CMML
A Phase 1 study of Leukemia and Myelodysplastic Syndrome, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT03770429: Active Phase 1 study of Leukemia and Myelodysplastic Syndrome, sponsored by Massachusetts General Hospital.
NCT03770429 is a Phase 1 study of Leukemia and Myelodysplastic Syndrome that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 52 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03770429, a Phase 1 study of Leukemia and Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
Primary Outcome
Incidence of dose limiting toxicities within the first 28 days of treatment, and enumeration of treatment emergent adverse events graded according to CTCAE
Conditions Studied
Interventions
- DRUG AZD6738
Study Locations (4)
Massachusetts
- BIDMC - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital Cancer Center - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What the registry record for NCT03770429 still lists
NCT03770429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AZD6738 is the first listed.
NCT03770429 reports a single indexed study location in Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT03770429 about?
NCT03770429 is a clinical study titled "AZD6738 for Patients With Progressive MDS or CMML". This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
What is the current status of trial NCT03770429?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-08-05. Estimated completion is 2026-05-31.
What conditions does trial NCT03770429 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndrome.
What interventions are being tested in trial NCT03770429?
The interventions under investigation include: AZD6738 (DRUG).
Who is sponsoring clinical trial NCT03770429?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03770429 being conducted?
This trial has 4 study locations across Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03770429's enrollment target sits among peer trials
52 109th of 233 higher than 124 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI